Clinical Trials Browser

Interventional × Sunitinib × 90 days × Clear all

NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,096 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT03899155 2026-05-27

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Phase 3 Recruiting

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05773274 2026-05-26

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05043090 2026-05-22

SAMETA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Phase 3 Active not recruiting

GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT06955169 2026-05-22

MOMENTUM-1

Phase 2 Suspended

Meningioma

NCT02693535 2026-05-15

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT00510640 2026-05-14

THYSU

Phase 2 Completed

Neoplasms, Thyroid Neoplasms

NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase 1 Recruiting

Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT06390826 2026-04-29

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Phase 2 Active not recruiting

10 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT00814021 2026-04-15

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Phase 2 Completed

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT04633122 2026-04-03

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Phase 2 Completed

108 enrolled 11 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT02555748 2026-03-31

SUP-R

Phase 4 Completed

Carcinoma, Renal Cell

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Phase 2 Active not recruiting

Advanced Rare Tumours

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT03463460 2026-03-23

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Phase 2 Active not recruiting

Thymoma

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

Neoplasm Metastasis, Osteosarcoma

NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Phase 2 Active not recruiting

Uveal Melanoma